Late Morbidity and Mortality in Patients with Hodgkin's Lymphoma Treated During Adulthood
Authors:
- Matthew J. MatasarMMMatthew J. Matasar
- Jennifer S. FordJFJennifer S. Ford
- Elyn R. RiedelERElyn R. Riedel
- Talya SalzTSTalya Salz
- Kevin C. OeffingerKOKevin C. Oeffinger
- David J. StrausDSDavid J. Straus
Open Access
- 6 February 2015
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 107 (4) , djv018
Abstract
Survivors of Hodgkin’s lymphoma (HL) treated as adults are at risk for late effects of therapy. However, the burden of late morbidity and mortality among adults treated for HL remains incompletely characterized. Vital status and, for deceased, cause of death were determined for 746 adults treated on a first-line trial at a single center from 1975 to 2000. Survivors completed a detailed survey describing their physical and mental health. A severity score (grades 1–4, ranging from mild to life-threatening or disabling) was assigned to self-reported conditions. At a median follow-up of 22 years, 227 of patients (30.4%) had died, 107 (47.1%) from HL, 120 (52.9%) from other causes, including second primary malignancies (SPMs) (n = 52) and cardiovascular disease (n = 27). Across the duration of follow-up, all-cause and SPM-specific risk of death remained higher than predicted by normative data. Among survivors, late morbidity survey data are available for 238 patients (45.9%). Ninety-four-point-one percent of respondents reported at least one morbidity, and 47.5% reported at least one grade 3 or 4 morbidity; 20.2% reported two or more grade 3 morbidities. Commonly reported morbidities included cardiovascular (54.6%), endocrine (68.5%), pulmonary disease (21.4%), and nonfatal second malignancy (23.1%). Anxiety, depression, and fear of recurrence were frequently reported. Among a large cohort of patients treated for HL with extensive follow-up, risk of late mortality from causes other than HL and prevalence of late medical morbidity are high. Guidelines for prevention, screening, and management of late effects in adult survivors of HL are needed.Keywords
This publication has 56 references indexed in Scilit:
- Long-term health-related outcomes in survivors of childhood cancer treated with HSCT versus conventional therapy: a report from the Bone Marrow Transplant Survivor Study (BMTSS) and Childhood Cancer Survivor Study (CCSS)Blood, 2011
- Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor StudyBlood, 2011
- Long-term Survivors of Childhood Ewing Sarcoma: Report From the Childhood Cancer Survivor StudyJNCI: Journal of the National Cancer Institute, 2010
- Mortality is persistently increased in Hodgkin’s lymphoma survivorsEuropean Journal of Cancer, 2010
- Escalated-Dose BEACOPP in the Treatment of Patients With Advanced-Stage Hodgkin's Lymphoma: 10 Years of Follow-Up of the GHSG HD9 StudyJournal of Clinical Oncology, 2009
- Health and persistent functional late effects in adult survivors of childhood CNS tumours: A population-based cohort studyEuropean Journal of Cancer, 2009
- High-Risk Populations Identified in Childhood Cancer Survivor Study Investigations: Implications for Risk-Based SurveillanceJournal of Clinical Oncology, 2009
- Psychological Status in Childhood Cancer Survivors: A Report From the Childhood Cancer Survivor StudyJournal of Clinical Oncology, 2009
- Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factorsBlood, 2002
- The Hospital Anxiety and Depression ScaleActa Psychiatrica Scandinavica, 1983